Changes in spleen cell type and number after treatment with rGM-CSF and rGM-CSF/rIL-4
| . | Cells (%) . | Total cells (× 106) . | ||||
|---|---|---|---|---|---|---|
| Control . | GM . | GM/IL-4 . | Control . | GM . | GM/IL-4 . | |
| B220 | 47.6 ± 14.8 | 42.5 ± 16 | 32.4 ± 5.6 | 25.1 ± 12.6 | 55.9 ± 22.6 | 22.1 ± 1.9 |
| Thy1.2 | 25.8 ± 3.4 | 24.7 ± 3.8 | 21.2 ± 1.2 | 13.0 ± 2.9 | 32.8 ± 5.2 | 14.6 ± 2.0 |
| NK1.1 | 2.2 ± 1.7 | 1.2 ± 1.0 | 5.2 ± 5.9 | 1.0 ± 0.6 | 1.5 ± 0.9 | 3.7 ± 4.6 |
| CD11b+ | 18.2 ± 7.5 | 23.9 ± 2.1 | 31.3 ± 11.9 | 9.2 ± 4.6 | 33.5 ± 6.2 | 21.7 ± 9.2 |
| Total | 93.8 ± 8.5 | 92.4 ± 18.4 | 90.1 ± 14.9 | 48.2 ± 14.2 | 123.7 ± 25.3 | 62.2 ± 13.6 |
| . | Cells (%) . | Total cells (× 106) . | ||||
|---|---|---|---|---|---|---|
| Control . | GM . | GM/IL-4 . | Control . | GM . | GM/IL-4 . | |
| B220 | 47.6 ± 14.8 | 42.5 ± 16 | 32.4 ± 5.6 | 25.1 ± 12.6 | 55.9 ± 22.6 | 22.1 ± 1.9 |
| Thy1.2 | 25.8 ± 3.4 | 24.7 ± 3.8 | 21.2 ± 1.2 | 13.0 ± 2.9 | 32.8 ± 5.2 | 14.6 ± 2.0 |
| NK1.1 | 2.2 ± 1.7 | 1.2 ± 1.0 | 5.2 ± 5.9 | 1.0 ± 0.6 | 1.5 ± 0.9 | 3.7 ± 4.6 |
| CD11b+ | 18.2 ± 7.5 | 23.9 ± 2.1 | 31.3 ± 11.9 | 9.2 ± 4.6 | 33.5 ± 6.2 | 21.7 ± 9.2 |
| Total | 93.8 ± 8.5 | 92.4 ± 18.4 | 90.1 ± 14.9 | 48.2 ± 14.2 | 123.7 ± 25.3 | 62.2 ± 13.6 |
Spleen cells were isolated and counted from mice treated with rGM-CSF or rGM-CSF/rIL-4 (10 μg/mouse per day for 7 days). Cells were analyzed by FACS for surface expression of various markers of B cells (B220), T cells (Thy1.2), NK cells (NK1.1), and myeloid cells (CD11b). Data represent the mean ± SD (n = 3 experiments).